Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels

Brain Research

Volumn 1185, Issue 1, 2007, Pages 18-32

  Vergo, Sandra ^a   Johansen, Jens Leander ^a   Leist, Marcel ^b   Lotharius, Julie ^a  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Dopamine; Lentivirus; Methamphetamine; Parkinson's disease; Primary mesencephalic neurons; VMAT2

Indexed keywords

DIGITONIN; DOPAMINE; LENTIVIRUS VECTOR; METHAMPHETAMINE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; SHORT HAIRPIN RNA; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL TISSUE; ARTICLE; CELL LEVEL; CELL MEMBRANE; CELL STRAIN; CELL SURVIVAL; CULTURE MEDIUM; CYTOSOL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; HOMEOSTASIS; MESENCEPHALON; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA;

ADRENERGIC UPTAKE INHIBITORS; ANALYSIS OF VARIANCE; ANIMALS; CELL PROLIFERATION; CYTOSOL; DOPAMINE; DRUG INTERACTIONS; GREEN FLUORESCENT PROTEINS; L-LACTATE DEHYDROGENASE; METHAMPHETAMINE; PC12 CELLS; POTASSIUM CHLORIDE; RATS; RESERPINE; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRANSFECTION; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

LENTIVIRUS; RATTUS;

EID: 36448961246     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.09.028     Document Type: Article

References (61)

1. Asanuma M., Miyazaki I., and Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox. Res. 5 (2003) 165-176
2. Bader M.F., Holz R.W., Kumakura K., and Vitale N. Exocytosis: the chromaffin cell as a model system. Ann. N.Y. Acad. Sci. 971 (2002) 178-183
3. Barzilai A., Melamed E., and Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?. Cell Mol. Neurobiol. 21 (2001) 215-235
4. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 (1999) 1127-1137
5. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
6. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., Mccormack A.L., Colebrooke R.E., Di Monte D.A., Emson P.C., and Miller G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27 (2007) 8138-8148
7. Chen C.X., Huang S.Y., Zhang L., and Liu Y.J. Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells. Neurobiol. Dis. 19 (2005) 419-426
8. Choi H.J., Lee S.Y., Cho Y., and Hwang O. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem. Int. 46 (2005) 329-335
9. Colebrooke R.E., Humby T., Lynch P.J., Mcgowan D.P., Xia J., and Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur. J. Neurosci. 24 (2006) 2622-2630
10. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
11. Cubells J.F., Rayport S., Rajendran G., and Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14 (1994) 2260-2271
12. Dittgen T., Nimmerjahn A., Komai S., Licznerski P., Waters J., Margrie T.W., Helmchen F., Denk W., Brecht M., and Osten P. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 18206-18211
13. Egashira T., and Yamanaka Y. Changes in monoamine oxidase activity in mouse brain associated with d-methamphetamine dependence and withdrawal. Biochem. Pharmacol. 46 (1993) 609-614
14. Eisenhofer G., Kopin I.J., and Goldstein D.S. Leaky catecholamine stores: undue waste or a stress response coping mechanism?. Ann. N.Y. Acad. Sci. 1018 (2004) 224-230
15. Erickson J.D., and Eiden L.E. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61 (1993) 2314-2317
16. Erickson J.D., Eiden L.E., and Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10993-10997
17. Fiskum G., Craig S.W., Decker G.L., and Lehninger A.L. The cytoskeleton of digitonin-treated rat hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 3430-3434
18. Fog J.U., Khoshbouei H., Holy M., Owens W.A., Vaegter C.B., Sen N., Nikandrova Y., Bowton E., Mcmahon D.G., Colbran R.J., Daws L.C., Sitte H.H., Javitch J.A., Galli A., and Gether U. Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51 (2006) 417-429
19. Fon E.A., Pothos E.N., Sun B.C., Killeen N., Sulzer D., and Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19 (1997) 1271-1283
20. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., and Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19 (1999) 2424-2431
21. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., and Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70 (1998) 1973-1978
22. Gandhi S., and Wood N.W. Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet. 14 Spec No. 2 (2005) 2749-2755
23. Glatt C.E., Wahner A.D., White D.J., Ruiz-Linares A., and Ritz B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum. Mol. Genet. 15 (2006) 299-305
24. Graham D.G., Tiffany S.M., Bell Jr. W.R., and Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14 (1978) 644-653
25. Holtje M., Von Jagow B., Pahner I., Lautenschlager M., Hortnagl H., Nurnberg B., Jahn R., and Ahnert-Hilger G. The Neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2). J. Neurosci. 20 (2000) 2131-2141
26. Holtje M., Winter S., Walther D., Pahner I., Hortnagl H., Ottersen O.P., Bader M., and Ahnert-Hilger G. The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake. J. Biol. Chem. 278 (2003) 15850-15858
27. Johnston T.H., and Brotchie J.M. Drugs in development for Parkinson's disease: an update. Curr. Opin. Investig. Drugs 7 (2006) 25-32
28. Jones S.R., Joseph J.D., Barak L.S., Caron M.G., and Wightman R.M. Dopamine neuronal transport kinetics and effects of amphetamine. J. Neurochem. 73 (1999) 2406-2414
29. Larsen K.E., Fon E.A., Hastings T.G., Edwards R.H., and Sulzer D. Methamphetamine-induced degeneration of dopaminergic Neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22 (2002) 8951-8960
30. Lavoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19 (1999) 1484-1491
31. Lavoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005) 1214-1221
32. Leander Johansen J., Dago L., Tornoe J., Rosenblad C., and Kusk P. A new versatile and compact lentiviral vector. Mol. Biotechnol. 29 (2005) 47-56
33. Leviel V. The reverse transport of DA, what physiological significance?. Neurochem. Int. 38 (2001) 83-106
34. Liu Y., and Edwards R.H. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20 (1997) 125-156
35. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., Brecha N., and Edwards R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70 (1992) 539-551
36. Lotharius J., and Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 11 (2002) 2395-2407
37. Lotharius J., and O'malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275 (2000) 38581-38588
38. Lotharius J., and O'malley K.L. Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann. Neurol. 49 (2001) 79-89
39. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., and Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277 (2002) 38884-38894
40. Lotharius J., Falsig J., Van Beek J., Payne S., Dringen R., Brundin P., and Leist M. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci. 25 (2005) 6329-6342
41. Miller G.W., Erickson J.D., Perez J.T., Penland S.N., Mash D.C., Rye D.B., and Levey A.I. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156 (1999) 138-148
42. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Fukuda M., Kitaichi K., Miyoshi K., and Ogawa N. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules. FASEB J. 20 (2006) 571-573
43. Mooslehner K.A., Chan P.M., Xu W., Liu L., Smadja C., Humby T., Allen N.D., Wilkinson L.S., and Emson P.C. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell Biol. 21 (2001) 5321-5331
44. Mosharov E.V., Gong L.W., Khanna B., Sulzer D., and Lindau M. Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. J. Neurosci. 23 (2003) 5835-5845
45. Mosharov E.V., Staal R.G., Bove J., Prou D., Hananiya A., Markov D., Poulsen N., Larsen K.E., Moore C.M., Troyer M.D., Edwards R.H., Przedborski S., and Sulzer D. Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 26 (2006) 9304-9311
46. Mundorf M.L., Hochstetler S.E., and Wightman R.M. Amine weak bases disrupt vesicular storage and promote exocytosis in chromaffin cells. J. Neurochem. 73 (1999) 2397-2405
47. Naldini L., Blomer U., Gage F.H., Trono D., and Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11382-11388
48. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
49. Pothos E.N. Regulation of dopamine quantal size in midbrain and hippocampal neurons. Behav. Brain Res. 130 (2002) 203-207
50. Pothos E.N., Larsen K.E., Krantz D.E., Liu Y., Haycock J.W., Setlik W., Gershon M.D., Edwards R.H., and Sulzer D. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20 (2000) 7297-7306
51. Rayport S., Sulzer D., Shi W.X., Sawasdikosol S., Monaco J., Batson D., and Rajendran G. Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology. J. Neurosci. 12 (1992) 4264-4280
52. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., Bieganski R.M., Lindquist S.L., and Lansbury P.T. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23 (2004) 23-34
53. Schuldiner S. A molecular glimpse of vesicular monoamine transporters. J. Neurochem. 62 (1994) 2067-2078
54. Stankovski L., Alvarez C., Ouimet T., Vitalis T., El-Hachimi K.H., Price D., Deneris E., Gaspar P., and Cases O. Developmental cell death is enhanced in the cerebral cortex of mice lacking the brain vesicular monoamine transporter. J. Neurosci. 27 (2007) 1315-1324
55. Sulzer D. alpha-Synuclein and cytosolic dopamine: stabilizing a bad situation. Nat. Med. 7 (2001) 1280-1282
56. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15 (1995) 4102-4108
57. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., and Uhl G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9938-9943
58. Weingarten P., Bermak J., and Zhou Q.Y. Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants. J. Neurochem. 76 (2001) 1794-1804
59. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
60. Zheng G., Dwoskin L., and Crooks P. Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 8 (2006) E682-E692
61. Zufferey R., Nagy D., Mandel R.J., Naldini L., and Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15 (1997) 871-875